Akihiko Seki1, Chigusa Shimono2. 1. Department of Medical Oncology, Suita Tokushukai Hospital, 21-1 Senriokanishi, Suita, Osaka, 565-0814, Japan. z4x3s2000@yahoo.co.jp. 2. Department of Medical Oncology, Suita Tokushukai Hospital, 21-1 Senriokanishi, Suita, Osaka, 565-0814, Japan.
Abstract
PURPOSE: To evaluate the hemostatic effects of transarterial infusion chemotherapy in addition to embolization (chemoembolization) for advanced primary lung cancer with tumor-related hemoptysis. MATERIALS AND METHODS: Ten consecutive patients with stage IIIB/IV or recurrent primary lung cancer (squamous cell carcinoma in six, adenocarcinoma in four) who underwent chemoembolization for control of hemoptysis were enrolled. At enrollment, five patients were considered refractory and five had contraindications to standard therapies. The amount of hemoptysis was massive in two patients, moderate in seven, and slight in one. Transarterial infusion chemotherapy via feeding arteries using cisplatin (25 mg/m2) and 5-fluorouracil (300 mg/m2) was repeated every 3-4 weeks for three cycles. HepaSphere (100-150 µm) or gelatin sponge particles were selected as embolic materials depending on the presence of pulmonary shunts and were added for embolization just after drug infusion. RESULTS: Hemoptysis improved in all patients (resolution in nine, significant decrease in one). The median hemostasis time was 11.9 months (range 2.7-25.9 months). The target pulmonary lesions shrank in seven patients, and pulmonary atelectasis disappeared in three of five patients. CONCLUSIONS: Chemoembolization may be a palliative option with favorable hemostasis time for advanced primary lung cancer with hemoptysis.
PURPOSE: To evaluate the hemostatic effects of transarterial infusion chemotherapy in addition to embolization (chemoembolization) for advanced primary lung cancer with tumor-related hemoptysis. MATERIALS AND METHODS: Ten consecutive patients with stage IIIB/IV or recurrent primary lung cancer (squamous cell carcinoma in six, adenocarcinoma in four) who underwent chemoembolization for control of hemoptysis were enrolled. At enrollment, five patients were considered refractory and five had contraindications to standard therapies. The amount of hemoptysis was massive in two patients, moderate in seven, and slight in one. Transarterial infusion chemotherapy via feeding arteries using cisplatin (25 mg/m2) and 5-fluorouracil (300 mg/m2) was repeated every 3-4 weeks for three cycles. HepaSphere (100-150 µm) or gelatin sponge particles were selected as embolic materials depending on the presence of pulmonary shunts and were added for embolization just after drug infusion. RESULTS: Hemoptysis improved in all patients (resolution in nine, significant decrease in one). The median hemostasis time was 11.9 months (range 2.7-25.9 months). The target pulmonary lesions shrank in seven patients, and pulmonary atelectasis disappeared in three of five patients. CONCLUSIONS: Chemoembolization may be a palliative option with favorable hemostasis time for advanced primary lung cancer with hemoptysis.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: N Tanaka; K Yamakado; S Murashima; K Takeda; K Matsumura; T Nakagawa; K Takano; M Ono; T Hattori Journal: J Vasc Interv Radiol Date: 1997 Jan-Feb Impact factor: 3.464
Authors: K Hayakawa; F Tanaka; T Torizuka; M Mitsumori; Y Okuno; A Matsui; Y Satoh; K Fujiwara; T Misaki Journal: Cardiovasc Intervent Radiol Date: 1992 May-Jun Impact factor: 2.740
Authors: Hong Suk Park; Young Il Kim; Hyae Young Kim; Jae-Ill Zo; Joo Hyuk Lee; Jin Soo Lee Journal: Cardiovasc Intervent Radiol Date: 2007 Jul-Aug Impact factor: 2.740
Authors: Thomas J Vogl; Thomas Lehnert; Stephan Zangos; Katrin Eichler; Renate Hammerstingl; Huedayi Korkusuz; Sebastian Lindemayr Journal: Eur Radiol Date: 2008-06-14 Impact factor: 5.315